Apogee Enterprises (NASDAQ: APOG) stock, a manufacturer of architectural glass and metal products for buildings, crashed 13.7 ...

Apogee Enterprises Inc (APOG) reports a 2.1% increase in net sales, driven by acquisitions and favorable product mix, while ...

Q3 2026 Management View Donald Nolan, CEO & Executive Chairman of the Board, began the call by announcing a leadership ...

This clinical-stage biotech focused on immunology therapies reported a notable insider sale amid ongoing pipeline development ...

Apogee Enterprises expects full-year earnings in the range of $3.40 to $3.50 per share. Apogee Enterprises shares have risen ...

Apogee also reduced its fiscal 2026 guidance, now expecting revenue of approximately $1.39 billion, down from previous estimates and below the analyst consensus of $1.41 billion. The company lowered ...

Phase 1b interim results of zumilokibart (APG777) in asthma demonstrated rapid and durable suppression of FeNO (key biomarker of Type 2 ...

Anticipation surrounds Apogee Enterprises's announcement, with investors hoping to hear about both surpassing estimates and receiving positive guidance for the next quarter. New i ...

Webcast Details Apogee Therapeutics’ live webcast of the APG777 Phase 1b asthma interim results will begin on Tuesday, January 6 th at 8:00 a.m. ET. The live webcast can be accessed via this link or ...

Apogee Therapeutics reports early trial data showing its asthma drug APG777 sharply reduced a key inflammation marker for up ...

Detailed price information for Apogee Therapeutics Inc (APGE-Q) from The Globe and Mail including charting and trades.